BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
1-Year Return
36.91%
This Quarter Return
+26.17%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$1.86B
AUM Growth
+$186M
(+11%)
Cap. Flow
-$192M
Cap. Flow
% of AUM
-10.3%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
2
Closed
–
Top Buys
| 1 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
+$10.7M |
Top Sells
| 1 |
STAAR Surgical
STAA
|
+$132M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$70.6M |
Sector Composition
| 1 | Healthcare | 63.23% |
| 2 | Consumer Staples | 22.77% |
| 3 | Industrials | 5.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
STAAR Surgical
STAA
$1.37B
| $1.01B | 53.49% |
9,544,091
-1,251,257
| -12% | -$132M |
|
2
Monster Beverage
MNST
$63.2B
| $424M | 22.55% |
9,312,976
| – | – |
|
|
3
iShares Russell 2000 ETF
IWM
$66.9B
| $152M | 8.1% |
690,000
-319,700
| -32% | -$70.6M |
|
4
Axon Enterprise
AXON
$59.4B
| $108M | 5.75% |
760,062
| – | – |
|
|
IMDX
5
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$88.1M
| $87.1M | 4.63% |
838,824
+103,014
| +14% | +$10.7M |
|
6
Lineage Cell Therapeutics
LCTX
$306M
| $79.9M | 4.25% |
34,005,379
| – | – |
|
7
Serina Therapeutics
SER
$53.2M
| $4.86M | 0.26% |
85,219
| – | – |
|